#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Cystic fibrosis lung Trigeminal neuralgia Cushing's syndrome Alexander disease Malignant peritoneal neoplasm Hereditary motor and sensory neuropathy Blastic plasmacytoid dendritic cell neoplasia Cholangitis sclerosing Pseudoxanthoma elasticum Cardiomyopathy Non-small cell lung cancer recurrent Marfan's syndrome Frontotemporal dementia Multifocal motor neuropathy Diffuse large B-cell lymphoma refractory More trials…

    Learn about Rare Diseases

    Advanced systemic mastocytosis – Diagnostics Burkitt’s lymphoma – Diagnostics Myelodysplastic syndrome with excess blasts – Basic Information Extranodal marginal zone B-cell lymphoma (MALT type) – Diagnostics Fragile X syndrome – Basic Information Atypical teratoid/rhabdoid tumour of CNS – Life with Disease Krabbe’s disease – Trials in Disease Cystic fibrosis – Diagnostics Paroxysmal nocturnal haemoglobinuria – Life with Disease Toxic epidermal necrolysis – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Lacnotuzumab Abrocitinib BNT327 VOROLANIB Azelastine Esomeprazole PF-07868489 Mps-102 Adagrasib Paroxetine Hydrochloride Tiotropium Bromide Pilocarpine Nitrate Ribociclib NALMEFENE HYDROCHLORIDE PIPOTIAZINE XENON (133XE) Bepirovirsen Flutamide Sulfonamides, Urea Derivatives Lavender Oil More therapies…

    Learn about Your Condition

    Metastasis Cutaneous calcification Joint stabilisation Rectal cancer stage II Albright's disease Infertility Aneurysm ruptured Tympanic membrane perforation High-grade B-cell lymphoma Pulmonary vascular disorder Alcohol abuse Hepatitis B Hairy cell leukaemia Glioblastoma Hepatotoxicity More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Haga Hospital

Haga Hospital

Els Borst-Eilersplein 275, Hague, 2545 AA, Netherlands

Want to learn more about this study or check if you can participate? Contact us.

  • Continued Darolutamide Treatment for Cancer Patients from Previous Bayer Studies

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Neoplasm malignant
    Investigated Drugs:
    • Darolutamide
    Belgium Bulgaria Czechia Estonia Finland France +11

  • Study Comparing Darolutamide and Androgen Deprivation Therapy to Placebo and Androgen Deprivation Therapy in Men with High-Risk Prostate Cancer Recurrence

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Prostate cancer recurrent
    Investigated Drugs:
    • Darolutamide
    • Gallium (68Ga) Gozetotide
    • Piflufolastat (18F)
    Austria Belgium Czechia Denmark Finland France +8

  • Study on Luspatercept and Epoetin Alfa for Treating Anemia in Patients with Low to Intermediate Risk Myelodysplastic Syndromes Needing Blood Transfusions

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Epoetin Alfa
    • Luspatercept
    Austria Belgium Czechia France Germany Greece +8

  • Study on Inclisiran for Preventing Heart Disease in High-Risk Patients

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Inclisiran
    Austria Belgium Bulgaria Croatia Czechia Denmark +14

  • Study of Belrestotug and Dostarlimab for Patients with Untreated Advanced Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Human Igg1 Kappa Monoclonal Antibody Against Tigit
    • Dostarlimab
    • Pembrolizumab
    Belgium Bulgaria Croatia Czechia Estonia Finland +14

  • Study on Midostaurin and Decitabine for Adults with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Who Are Unfit for Intensive Treatment

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Acute myeloid leukaemia
    • Myelodysplastic syndrome
    Investigated Drugs:
    • Decitabine
    • Midostaurin
    Belgium The Netherlands

  • Long-term safety and efficacy study of elexacaftor/tezacaftor/ivacaftor treatment in people with cystic fibrosis who have non-F508del genetic mutations

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Cystic fibrosis
    Investigated Drugs:
    • Elexacaftor
    • Tezacaftor
    • Ivacaftor
    Austria Belgium Czechia France Germany Hungary +7

  • Study on Ibrutinib and Drug Combination for Patients with Generalized Mantle Cell Lymphoma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Mantle cell lymphoma stage II
    • Mantle cell lymphoma stage III
    • Mantle cell lymphoma stage IV
    Investigated Drugs:
    • Ibrutinib
    Belgium Czechia Denmark Finland Germany Italy +6

  • Study on Asundexian and Apixaban for Preventing Stroke in Adults with Atrial Fibrillation at Risk for Stroke

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Asundexian
    • Apixaban
    Austria Belgium Bulgaria Czechia Denmark Estonia +16

  • Study of pelacarsen and inclisiran in patients with atherosclerotic cardiovascular disease who have high levels of LDL cholesterol and lipoprotein(a)

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Arteriosclerosis
    Investigated Drugs:
    • Pelacarsen
    • Inclisiran
    France Germany Italy The Netherlands Spain
Previous Page
1 … 11 12 13 14
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!